Apellis Pharmaceuticals
APLS

$39.75

2.24%

Market Cap: 4.82B

About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Employees: 702

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 26 analysts

0

News positive %

of 7 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

32% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 50

17% more call options, than puts

Call options by funds: $111M | Put options by funds: $94.7M

15% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 89

6% more funds holding

Funds holding: 278 [Q4 2023] → 294 (+16) [Q1 2024]

3% less capital invested

Capital invested by funds: $6.81B [Q4 2023] → $6.58B (-$231M) [Q1 2024]

3.09% less ownership

Funds ownership: 95.99% [Q4 2023] → 92.9% (-3.09%) [Q1 2024]

11% less funds holding in top 10

Funds holding in top 10: 9 [Q4 2023] → 8 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

26 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$46

16%

upside

Avg. target

$78

96%

upside

High target

$100

152%

upside

26 analyst ratings

19 positive

73%

7 neutral

27%

0 negative

0%

Baird Colleen Kusy	116%upside $86	Outperform Maintained	26 Jul 2024
Baird Colleen Kusy	152%upside $100	Outperform Maintained	23 Jul 2024
Goldman Sachs Salveen Richter	94%upside $77	Buy Maintained	17 Jul 2024
Baird Colleen Kusy	152%upside $100	Outperform Maintained	28 Jun 2024
Piper Sandler Biren Amin	16%upside $46	Neutral Initiated	31 May 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about APLS published over the past 30 days

Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK , July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Apellis insiders caused the company to misrepresent or fail to disclose that (1) the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, statements about the company's business, operations, and prospects lacked a reasonable basis.

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET.

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

WALTHAM, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that six abstracts, five of which are oral presentations, will be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 17 - 20 in Stockholm, Sweden. These data reinforce the robust efficacy and well-documented safety profile of SYFOVRE® (pegcetacoplan injection) for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Zacks Investment Research

Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe

Apellis' (APLS) revenues rise on the back of the robust uptake of Syfovre for the GA indication. However, the recent regulatory setback in the EU for pegcetacoplan to treat GA is a woe.

Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe

Zacks Investment Research

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA).

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

Zacks Investment Research

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

Zacks Investment Research

Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?

Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET.

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

See News Rankings